DRUG · Mapped RxNorm record
osimertinib
Normalized identity: osimertinibView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers
NCT02803203
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Bevacizumab
Normalized identity: bevacizumabView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedOsimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1, PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Interventions
osimertinibDRUG · verified · RxNorm: osimertinib
BevacizumabDRUG · verified · RxNorm: bevacizumab
Sponsors & collaborators
Memorial Sloan Kettering Cancer Centerlead sponsor
AstraZenecacollaborator
Genentech, Inc.collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02803203 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.